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Trial Protocol: A randomised controlled trial of
extended anticoagulation treatment versus routine
anticoagulation treatment for the prevention of
recurrent VTE and post thrombotic syndrome in
patients being treated for a first episode of
unprovoked VTE (The ExACT Study)
Jayne Tullett1, Ellen Murray1*, Linda Nichols1, Roger Holder1, Will Lester2, Peter Rose3, FD Richard Hobbs4
and David Fitzmaurice1
Abstract
Background: Venous thromboembolism comprising pulmonary embolism and deep vein thrombosis is a
common condition with an incidence of approximately 1 per 1,000 per annum causing both mortality and
serious morbidity. The principal aim of treatment of a venous thromboembolism with heparin and warfarin is to
prevent extension or recurrence of clot. However, the recurrence rate following a deep vein thrombosis remains
approximately 10% per annum following treatment cessation irrespective of the duration of anticoagulation
therapy. Patients with raised D-dimer levels after discontinuing oral anticoagulation treatment have also been
shown to be at high risk of recurrence.
Post thrombotic syndrome is a complication of a deep vein thrombosis which can lead to chronic venous
insufficiency and ulceration. It has a cumulative incidence after 2 years of around 25% and it has been suggested
that extended oral anticoagulation should be investigated as a possible preventative measure.
Methods/design: Patients with a first idiopathic venous thromboembolism will be recruited through
anticoagulation clinics and randomly allocated to either continuing or discontinuing warfarin treatment for a
further 2 years and followed up on a six monthly basis. At each visit D-dimer levels will be measured using a
Roche Cobas h 232 POC device. In addition a venous sample will be taken for laboratory D-dimer analysis at the
end of the study. Patients will be examined for signs and symptoms of PTS using the Villalta scale and complete
VEINES and EQ5D quality of life questionnaires.
Discussion: The primary aim of the study is to investigate whether extending oral anticoagulation treatment
(prior to discontinuing treatment) beyond 3–6 months for patients with a first unprovoked proximal deep vein
thrombosis or pulmonary embolism prevents recurrence. The study will also determine the role of extending
anticoagulation for patients with elevated D-dimer levels prior to discontinuing treatment and identify the
potential of D-dimer point of care testing for identification of high risk patients within a primary care setting.
(Continued on next page)
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Background
Venous thromboembolism (VTE) is associated with
significant mortality and morbidity, including post-
thrombotic syndrome (PTS). VTE is considered as a
chronic disease with pulmonary embolism (PE) and
deep vein thrombosis (DVT) being different manifes-
tations of the same disease process.
Currently, patients with a first episode of unpro-
voked proximal DVT or PE, with no apparent other
risk factors for recurrent VTE, are given a course of
oral anticoagulation (warfarin in the UK) treatment
which is then discontinued. The optimum duration of
warfarin therapy depends on the individual patient and
has not been defined [1]. Concern in terms of duration
of treatment is due to the risk of bleeding from
prolonged warfarin treatment. Several studies have inves-
tigated the optimal duration of anticoagulant therapy
with the British Committee for Standards in Haematol-
ogy (BCSH, 1998) recommending between six weeks and
six months, depending upon the aetiology [2,3].
A substantial proportion of patients – up to 17%
[4-7] go on to have a recurrent episode of VTE which
can be a potentially life-threatening condition [8]. If
recurrence occurs, the patient is normally managed
thereafter with long-term warfarin, provided there are
no contraindications. Although optimal duration of
anticoagulation treatment for patients with a first idio-
pathic VTE remains uncertain, randomised trials have
suggested that patients should be treated for a mini-
mum of three months [9] but beyond that the dur-
ation of anticoagulation has little effect on the rate of
recurrence3. There is an annual recurrence rate follow-
ing a first VTE of approximately 10% per annum fol-
lowing treatment cessation, irrespective of the duration
of warfarin therapy [10]. This suggests that some pa-
tients with a first unprovoked VTE should continue
warfarin in the long-term however we are currently
unable to identify this population. Studies of extended
treatment with low dose warfarin have confirmed that
maximal benefit is conferred at standard therapeutic
targets rather than fixed low dose regimes [11,12].
It would be very useful to have an accurate predictor
of recurrence of VTE to decide which patients with a
first episode of unprovoked proximal DVT or PE
would be most likely to benefit from long term oral
anticoagulation, and also which patients should only
receive short term therapy.
D-dimer is a fibrin degradation product, present in
the blood after a blood clot is degraded by fibrinolysis
and levels of D-dimer can be tested using laboratory
and point-of-care (POC) testing devices. The primary
clinical use of D-dimer testing has been in conjunction
with probability scores to determine whether further in-
vestigation is required for the diagnosis of VTE. More re-
cently interest has been shown in studies which have
investigated whether D-dimer can be utilised as a guide
for determining who is at risk of recurrent VTE following
treatment of the initial acute episode [13,14].
Previous small studies outside the UK have suggested
that D-dimer levels could act as a useful predictor of re-
current thromboembolism in patients whose warfarin is
discontinued [14-16]. There are limited data on utility of
the D-dimer as a predictor in patients still on therapy,
but Rodgers et al. have shown that D-dimer can be used
to predict recurrence in low risk female patients [17]. In
addition to D-dimer levels a recent meta-analysis has
suggested that age and gender may be effective in
predicting recurrent VTE [18]. This study concluded
that men are at greater risk of developing a recurrent
VTE after a first unprovoked episode and that age could
be used as predictor in women. Therefore D-dimer
levels could be a potentially useful clinical tool to decide
which patients, with a first episode of unprovoked prox-
imal DVT or PE, would most likely benefit from long-
term warfarin therapy.
The conclusions of 2 systematic reviews of D-dimer
testing after stopping treatment for VTE, (7 studies with
a total of 1888 patients) were: “additional research is
needed to establish the optimal interval between stop-
ping anticoagulation and performing D-dimer testing, to
identify the optimum cut-off that predicts recurrence
and to develop a clinical prediction rule for recurrent
DVT.” [19], and “strategies which incorporate a number
of high performing baseline and post-baseline predictors
could be more effective in predicting recurrent VTE and
should be tested. If oral anticoagulation is continued,
there is no evidence on the duration of this extended
therapy [20].”
The only UK data included in these reviews were
from a prospective cohort study of 272 patients with a
first episode of venous thrombosis that was unprovoked
or provoked by a non-surgical trigger. They undertook
D-dimer testing 1 month after cessation of warfarin ther-
apy and found a non-significant difference in recurrence
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(5.5/100 patients years in D-dimer + ve vs. 4.1/100
patient years in D-dimer –ve) [10].
PTS is a frequent and costly complication of DVT
which can lead to chronic venous insufficiency and ul-
ceration. PTS has a cumulative incidence after 2 years
of around 25% and it has been postulated that
prolonged treatment with oral anticoagulants could pre-
vent the development of PTS [21]. The only data avail-
able from a randomised trial suggested no association
between long-term low dose warfarin treatment and de-
velopment of PTS [22]. The prevalence of PTS in this
study was 37% after 2.2 years, with severe PTS in 4%. A
recent study demonstrated an association between D-
dimer level and the development of PTS [23], this is
something that will be investigated during the course of
this study.
Methods
Aims and objectives
Considering patients with a first unprovoked proximal
DVT and PE who have been treated with 3–6 months
oral anticoagulation, the aims of the study are:
 To investigate the effect of extending treatment with
oral anticoagulation in terms of reduction in
incidence of VTE and PTS
 To develop an algorithm to predict high/low
recurrence rates in these patients
As part of this we will be investigating the following:
 To establish the performance characteristics of
D-dimer testing whilst still on treatment as a
prediction tool for recurrence of VTE in patients
with first unprovoked proximal DVT or PE.
 To establish factors which contribute to the
recurrence of VTE in patients with a first
unprovoked proximal DVT or PE.
 To determine the cost-effectiveness of the
measurement of D-dimer and subsequent extended
treatment with anticoagulation.
 To determine patient preferences and utilities with
regard to extended warfarin treatment.
Participants
Patients will be recruited through a number of primary
care and secondary care anticoagulation clinics in the
wider Midlands area over a two year period.
Patients identified as receiving warfarin for a first un-
provoked proximal DVT or PE and who are eligible for
the trial (Table 1) will receive a brief information sheet
about the study during their anticoagulant clinic ap-
pointment. They will also be given a post card to return
to the research department stating their willingness in
principle to take part in the study, for their GP to be
contacted and their records to be accessed for the pur-
pose of checking their eligibility for the study. The pa-
tients GP will simultaneously be sent a summary of the
trial and informed that one of their patients wishes to
participate. The GP will be asked to complete a form to
state whether they wish their practice to take part in
the study.
Those patients who reply with a positive response
from willing general practices will be contacted to deter-
mine that they still wish to take part in the study. If still
willing to take part then the research nurse or a member
of the practice staff will access the patients’ primary care
notes to assess their eligibility for inclusion into the
study. If the patient is eligible then they will be followed
up (at least 1 month before the end of their current
treatment) to arrange their first visit to the GP surgery.
Any additional travel costs and prescription costs will be
paid to the patient from study funds.
Those with a negative reply will not be contacted.
Those patients who do not return their postcard will be
given a second postcard a month after the first one was
given out. If a patient wishes to take part in the study
but their GP is unwilling, alternative arrangements will
be made at a hospital clinic.
The first appointment at the GP clinic will inform as
to the nature of the trial. For those patients willing to
participate the research nurse will obtain written in-
formed consent.
Trial intervention
Study participants will have a total of six visits over a
two year period.
Visit 1
This is the same visit as the information, consent and
randomisation visit and will be within 2 weeks of current
anticoagulation treatment end date. Patients will be
randomised electronically into one of two groups; Group
O will discontinue warfarin after their usual clinical
intervention, Group W will continue warfarin for a fur-
ther two years.
Patients will be interviewed to collect the following
data:
Concomitant medications; ethnicity; smoking status;
alcohol consumption; medical history; BMI; and family
history of VTE
A heparinised venous sample of blood will be taken
for a D-dimer test on a POC device (Cobas h 232, Roche
diagnostics). In addition citrated venous samples will be
collected for D-dimer testing. These will be sent to a
central laboratory to be frozen and stored for analysis
during and at the end of the study.
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The D-dimer result will be recorded centrally onto a
database for future analysis and both patient and re-
searcher will be blinded as to the result of this test.
All patients will be clinically examined for signs and
symptoms of PTS using a validated clinical scoring system
(the Villalta scale) and will also complete the VEINES qual-
ity of life score [24] as well as EQ 5D which allows the
measurement of broad aspects of quality of life [25]. In
addition the patients will complete a costs questionnaire
relating to the expenses incurred on a recent
anticoagulation clinic visit. Where questionnaires are in-
complete or unclear the patients will be contacted by tele-
phone to clarify and complete the responses.
Compression stockings will be used by patients as ad-
vised by the clinician treating the DVT and the re-
searchers will not influence their utilisation.
The anticoagulation clinic that the patient would nor-
mally attend will be informed that the patient is entering
a study as will any specific hospital consultants who are
involved with the patients’ care (e.g. haematologists).
Patients randomly allocated to Group W will be
followed-up through their usual oral anticoagulation
service provided in terms of warfarin management and
the anticoagulation clinic lead will be asked to extend
their clinic visits for a further 2 years. Patients ran-
domly allocated at this point to Group O will undergo
a further D-dimer test 1 month after cessation of treat-
ment. Again both researcher and patient will be blinded
to this result.
Visits 2–6
All patients randomised (Groups W and Group O) will
be reviewed every 6 months for 2 years in total to assess
evidence of VTE recurrence, clinical assessment of PTS,
and measurement of D-dimer (again patient and re-
searcher are blinded to these results).
Table 1 Study inclusion and exclusion criteria
Inclusion criteria People aged 18 years or over with a diagnosis of first unprovoked* proximal** DVT or PE on treatment with anticoagulants
Have completed 3 – 6 months of anticoagulant therapy (target 2–3)
*The episode will be defined as unprovoked as long as there is no history within the previous 3 months of:
major surgery; lower limb trauma e.g. fracture, cast, limping for 3 days; use of the combined oral contraceptive pill
or hormone replacement therapy ; pregnancy; significant immobility e.g. confined to bed for 3 days; active cancer.
**Proximal refers to a DVT alone in the trifurcation area, popliteal, superficial femoral, deep femoral, common femoral
and iliac veins.
Exclusion criteria Patients under the age of 18 years
Patients with another indication for long term warfarin therapy e.g. Atrial Fibrillation
Patients with a diagnosis of first unprovoked proximal DVT or PE who are no longer on anticoagulation therapy
Patients with a high risk of bleeding as evidenced by any of the following:
• Patients with a previous episode of major bleeding where the cause was not effectively treated
• Known thrombocytopaenia with a platelet count of less than 120 ×109 /L
• Known chronic renal failure with a creatinine of more than 150 μmols/L (1.7 mg/dl) or eGFR less than 30
• Known chronic liver disease with a total bilirubin of more than 25μmols/L (1.5 mg/dl)
• Active peptic ulcer
• Patients requiring antiplatelet therapy (eg Aspirin and/or Clopidogrel)
Patients with a vena cava filter in place
Patients who have had a D–dimer test performed within 2 months of potential enrolment other than for evaluation
for suspected recurrent VTE that was not confirmed
Patients whose GP expects their life expectancy to be less than 5 years
Patients unable to attend follow up visits due to geographic inaccessibility
Patients participating in a competing investigation
Patients with known antiphospholipid syndrome
If patients are subsequently found to have antiphospholipid syndrome then they will have to be excluded.
Patients with known inherited protein C and/or protein S or antithrombin deficiency
If patients are subsequently found to have protein C and/or protein S or anithrombin deficiency then they will have
to be excluded.
Patients with a diagnosis of active cancer
Patients unwilling to give consent
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All patients will again be asked to complete the
VEINES-QOL/Sym a validated disease specific, quality
of life score, and EQ 5D, questionnaires.
If a patient in Group O (off warfarin) has their
warfarin restarted by their GP during the study
period for a VTE recurrence then they will be re-
moved from the study but a case review will be car-
ried out in patient’s primary care notes looking for
evidence of thrombotic events. If a patient in Group
O has to restart warfarin for another reason e.g.
atrial fibrillation, then they will continue to be
followed up in the usual manner. If a patient in
Group W (on warfarin) has to permanently stop tak-
ing their warfarin during the study then they will be
followed up and included in the final analysis on an
intention to treat basis. If a patient in Group W has
a temporary break in their treatment for any reason,
they will continue to follow the same visit regime,
making a note of the temporary break.
Patients in Group W will be asked to return for a final
D-dimer test 1 month after discontinuing warfarin.
Patients randomised into group W will continue with
their warfarin management as before. INR data will be
collected from the anticoagulation database at six
monthly intervals throughout the study to assess overall
control.
Outcome measures
Primary outcomes
1. Number of recurrent thrombotic events between
those with raised D-dimer at point of
randomisation who were randomly allocated to
the treatment arm (group RW) and those with
raised D-dimer at point of randomisation who
were randomly allocated to the no treatment arm
and produced a normal D-dimer off treatment
(NRO) and those with raised D-dimer at point of
randomisation who were randomly allocated to
the no treatment arm and then produced a raised
D-dimer off treatment (RRO) (see Figure 1)
2. Number of recurrent thrombotic events between
those showing an elevated D-dimer off treatment
(RO) versus those showing a negative D-dimer off
treatment (NO) (see Figure 1)
Secondary outcomes
1. Severity of PTS between groups
2. Bleeding events - defined as in Table 2
3. INR control in terms of percentage time in range
4. Optimal cut off on a D-dimer result
5. Costs of D-dimer and subsequent extended
treatment with anticoagulation
6. Cost effectiveness
7. Information on the types of patient who potentially
benefit from extended warfarin treatment, age and
gender
8. Patient quality of life
Ascertainment of outcomes
D-dimer results
All baseline and six monthly D-dimer results will be
recorded onto the trial database by practice staff.
Thrombotic events and associated deaths
 At six monthly intervals and at the end of the study
patient GP records will be reviewed for any mention
of hospital admission, to ascertain any thrombotic
events including fatalities, and whether they are still
taking warfarin.
 When hospitalisation or death is identified in the
study population, a discharge summary and a copy
Unprovoked DVT/PE
N=704
Assume 50% take-up
Patient recruited into study
D-dimer testing on treatment
N=352
50% No treatment
Group O
N=176
D-dimer test 1/12 off 
treatment
N= 176
4 x 6/12 assessment
D-dimer, QOL,PTS etc
24 month follow up
Groups 
NNO,RNO,NRO,RRO
N = 158
50% Warfarin
Group W
N=176
4 x 6/12 assessment
D-dimer, QOL,PTS etc
D-dimer test 1/12 off 
treatment
N=176
24 month follow up
Groups NW and RW
N  =158
Figure 1 Flow chart for trial intervention.
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of the death certificate (if applicable) will be
obtained. (The patients’ NHS numbers will be
flagged at the Medical Research Information Service
to inform on cause of death).
 These will be scrutinised by the Independent
Adverse Event committee who will be blinded to the
treatment allocation. The committee will decide
what was the primary cause of hospitalisation/death.
This committee will meet once all the data has been
collected.
 Research nurses will abstract other information
concerning the hospital admission, including
admission and discharge dates, and discharge
destination. Date of death will be recorded.
Recurrence will need to be objectively documented
(i.e. defined radiologically). Radiological criteria for
recurrent DVT will be: a new non-compressible ven-
ous segment compared to the examination at base-
line; an increase of 4 mm or more in thrombus
diameter with compression; or, a convincing exten-
sion in length.
INR control
Patients INR results, with the amount of warfarin taken,
will be collected onto the trial database at 6 months,
18 months and at the end of the study.
Patient quality of life
This will be assessed by all patients completing ques-
tionnaires at each study visit.
Veines-QOL/Sym a validated disease specific quality
of life questionnaire will be used as well as EQ-5D al-
lows changes in health status to be measured but also
valued, using the University of York Measurement &
Valuation of Health general population survey tariff.
Where questionnaires are incomplete or unclear the
patients will be contacted by telephone to clarify and
complete the responses.
Incidence and severity of PTS
Measured using a validated clinical scoring system (the
Villalta scale). Signs will be measured on both legs [26].
Cost data
The cost analysis will adopt a broad perspective to in-
clude costs incurred within the health sector and by
patients. Health sector costs will include additional
costs of D-dimer testing and prolonged treatment
(anticoagulation) costs. Patient level data will be col-
lected on treatment and condition-specific health service
utilisation (primary and secondary care), thrombotic epi-
sodes, PTS and bleeding events. Information on costs in-
curred by patients when attending anticoagulation clinics
(e.g. time and travel costs) will also be collected with a
Table 2 Definition of bleeding events
Major bleeding Clinically overt bleeding that is associated with:
A fall in haemoglobin of 2 g/dl or more, or
A transfusion of 2 or more units of packed red blood cells or whole blood, or
A critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with
compartment syndrome, retroperitoneal, or
A fatal outcome
Non-major clinically relevant bleeding Non-major clinically relevant bleeding is defined as overt bleeding not meeting the criteria
for major bleeding but associated with medical intervention, unscheduled contact (visit or
telephone call) with a clinician, (temporary) cessation of warfarin treatment, or associated
with discomfort for the subject such as pain or impairment of activities of daily life.
Examples of non-major clinically relevant bleeding are:
• Epistaxis if it lasts for more than 5 minutes, if it is repetitive (i.e., 2 or more episodes of true
bleeding, i.e., not spots on a handkerchief, within 24 hours), or leads to an intervention
(packing, electrocautery, etc.) and no admission to hospital.
• Gingival bleeding if it occurs spontaneously (i.e., unrelated to tooth brushing or eating),
or if it lasts for more than 5 minutes
• Haematuria if it is macroscopic, and either spontaneous or lasts for more than 24 hours
after instrumentation (e.g., catheter placement or surgery) of the urogenital tract
• Macroscopic gastrointestinal haemorrhage: at least 1 episode of melena or hematemesis,
if clinically apparent
• Rectal blood loss, if more than a few spots
• Haemoptysis, if more than a few speckles in the sputum, or
• Intramuscular hematoma
• Subcutaneous hematoma if the size is larger than 25 cm2 or larger than 100 cm2 if provoked
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patient cost questionnaire. Information on resource use
will be collected from patient notes. Unit costs will be
obtained from standard sources and health care
providers.
Sample size
Initially, patients will be randomly assigned to warfarin
(Group W) or no treatment (Group O) arms Following
the flow chart for analysis (Figure 1) will result in 6
study populations, those with normal D-dimer at point
of randomisation who were randomly allocated to the
warfarin treatment arm (group NW), those with ele-
vated D-dimer at point of randomisation who were
randomly allocated to the treatment arm (group RW),
those with normal D-dimer at point of randomisation
who were randomly allocated to the no treatment arm
and then produced a normal D-dimer off treatment
(NNO), those with normal D-dimer at point of ran-
domisation who were randomly allocated to the no
treatment arm and then produced an elevated D-dimer
off treatment (RNO), those with elevated D-dimer at
point of randomisation who were randomly allocated to
the no treatment arm and produced a normal D-dimer
off treatment (NRO) and those with elevated D-dimer at
point of randomisation who were randomly allocated
to the no treatment arm and then produced an ele-
vated D-dimer off treatment (RRO). (Thus in the two
or three letter code the last letter indicates the arm
a patient is randomised to, the previous letter indi-
cates the outcome of the D- dimer test performed on
the same visit as randomisation and, in the case of
those randomised to no further treatment, the first
letter relates to the D-dimer result produced after
randomisation). A 10% loss to follow up rate is as-
sumed from the beginning of the trial. The Data
Safety Monitoring Board will inform the research
team if recruitment is below target as the study pro-
gresses and if so further hospitals will be recruited.
Total sample size will be sufficiently large to show
a significant difference in recurrence rates between
those showing a positive D-dimer on treatment who
receive warfarin (RW) and those showing a positive
D-dimer who receive no treatment (RNO plus RRO).
Following Palareti [7] this means a sample size for
each group of 79 in order to give 90% power to a
5% significance test when comparing 2 year recur-
rence rates of 21.4% and 4.3%. Assuming a 50% posi-
tive D-dimer rate this implies a total of 79 × 2 × 2/
0.9 = 352 patients taking part in the study (and 316
completing the study). Allowing a 50% participation
rate this means that 704 patients need to be
approached initially. With such a sample size an overall
comparison of recurrence rates between the arms W
and O can be made with power of between 86 and 99%
assuming recurrence rates of between 1.4% and 4.3%
for the warfarin arm (Group W, depending on what re-
currence rate patients with normal D-dimer on war-
farin produce) and 14.2% for the No treatment arm.
One of the objectives of the study is to determine an
optimal cut off on a D-dimer result taken when the pa-
tient is receiving treatment. In a study of 272 patients,
Baglin et al. report that 170/272 patients had a D-dimer
in excess of 500 ng mL-1 and their ROC analysis sug-
gests an optimal cut off of 500 ng/ml [10]. The circum-
stances of their study differ from ours but using their
data will give some indication of the precision with
which we will be able to estimate an optimal cut off with
slightly more patients than Baglin et al. With some as-
sumptions, a rough calculation of the precision with
which a cut off in the region of 500 could be estimated
with our sample size of 316 would be within about 7%
(95% confidence interval).
Randomisation
Randomisation will be performed within the computerised
clinical case report form (CRF) produced in Primary Care
Clinical Sciences, University of Birmingham. When a pa-
tient is identified as being eligible for the study and has
given written consent to take part, the research nurse will
enter details into the computerised CRF and will be issued
immediately with a dedicated randomisation code allocat-
ing the patient to either continuing warfarin therapy or
stopping warfarin therapy.
Patients will be randomly allocated at this point to ei-
ther continue warfarin (Group W) for a further 2 years
or to discontinue treatment (Group O). Randomisation
will be stratified by DVT and PE to ensure there are
equal numbers in both groups W and O.
Analysis and statistical methods
Intention to treat analysis will be used. The types of ana-
lysis proposed are Chi-square, generalized linear models,
logistic regression and survival analysis, t-tests, ANOVA
and non-parametric equivalents.
Analysis will be carried out at the end of the study, as
there is likely to be insufficient power for interim analyses.
Quality control of data collection will be conducted by a
trial management committee throughout the study and by
a statistician independent of the research team.
Logistic regression would be used to relate D-dimer re-
sult and other patient data to events such as recurrence,
bleeding episodes and PTS separately on the two arms
(Group W and Group O) of the trial and together. Baglin
et al [10], with their 272 patients, showed a significant
association between age and D- dimer (p < 0.001) and
our total sample, allowing for loss to follow up, of 316
should be ample to incorporate such a relationship. In
comparing D-dimer levels between genders they achieved
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a significance level of p = 0.18 with 272 individuals. A
rough calculation would suggest a p value of 0. 15 for
the same level of difference in D-dimer (approximately
80 ng/ml) in our total sample of 316 patients.
Cost effectiveness analysis
The analysis will determine the cost-effectiveness of
the measurement of D-dimer and subsequent extended
treatment with anticoagulation. Data collection will be
for all trial patients so that a stochastic cost analysis
can be undertaken. A cost-consequence analysis will
initially be reported, describing all the important re-
sults relating to costs and consequences. Subsequently,
a cost-effectiveness analysis will be conducted using
data on the clinical events of interest (thrombotic and
bleeding events). An incremental analysis will be
undertaken to calculate the cost per major outcome
averted. A cost-utility analysis will also be undertaken
using patient responses to the EQ-5D questionnaire, to
calculate the cost per additional Quality-Adjusted Life
Year (QALY) gained.
The analysis will be from an NHS perspective, how-
ever patient costs will be incorporated in a sensitivity
analysis in order to consider cost-effectiveness from a
broader perspective. The data for costs is likely to have a
skewed distribution therefore the plan is to explore the
nature of the distribution of costs. If the data is not nor-
mally distributed, the non parametric comparison of
means (e.g. bootstrapping) will be undertaken. Efforts
will be made to minimise the problem of missing data,
but if this does pose a problem at the economic analysis
stage then imputation techniques will be used.
In addition to the trial-based economic evaluation,
longer term costs and consequences will be explored by
extrapolating beyond the end of the trial. Decision mod-
elling will be undertaken using data from the trial and
from non-trial sources, in order to determine the long-
term cost-effectiveness of the intervention, with results
reported as cost per additional QALY gained.
The robustness of the results will be explored using
sensitivity analysis. This will explore uncertainties in the
trial based data itself, the methods employed to analyse
the data and the generalisability of the results to other
settings. Uncertainty in the confidence to be placed on
the results of the economic analysis will be explored by
estimating cost effectiveness acceptability curves. These
plot the probability that the intervention is cost effective
against threshold values for cost effectiveness.
Data validation
Data cleaning will take place by a series of logical checks
on the electronic data using specific queries. Discrepant
data entries will be checked with the source documents
and the database amended if necessary.
Data management, protection and confidentiality
The data management is fully compliant with the Data
Protection Act and ICH GCP. The trial is registered with
Legal Services at the University of Birmingham who are
responsible for ensuring that the purposes for which the
University processes personal data is registered with the
Information Commissioners office.
Submissions will be made to the NHS IC Medical Re-
search Information Service for flagging deaths, exits
from and re entries to the NHS, including PCT data.
Time plan
It is anticipated that patient recruitment will take place
over a 2 year period. Patient follow-up will then continue
for a further 2 years.
Assessment of safety
Participants safety will be ensured by screening for eligi-
bility using a structured form completed by trial
healthcare professionals. This will record evidence of eli-
gibility and the presence/absence of any inclusion and
exclusion criteria. The Research Associates and Nurses
will take a general medical and drug history to assess for
other complicating diseases and medications. Any quer-
ies will be discussed with the trial nurse, chief investiga-
tor and the relevant physicians at the trial site. The
eligibility will be signed off by the physician providing
routine medical care.
Adverse event reporting
Data will be collected for all serious adverse events
(SAE), non-serious adverse reactions (NSAR), serious
adverse reactions (SAR) and SUSAR as defined in
Table 3. Adverse events (AEs), SAEs and suspected un-
expected serious adverse reactions (SUSARs) will be
reported in compliance with International Conference
on Harmonisation (ICH)- Good Clinical Practice (GCP)
Guidelines.
Ethics and research governance
The trial will be conducted in compliance with the prin-
ciples of the Declaration of Helsinki (1996), the princi-
ples of the ICH-GCP and run in accordance with EU
Clinical Trials Directive and all of the applicable regula-
tory requirements. The study protocol and other docu-
mentation have been approved by Trent Research Ethics
Committee and MHRA.
Publication
The trial results will be written up for submission to a
peer reviewed journal and the trial is registered with
ISRCTN. No data relating to individuals will be identi-
fied in these publications.
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Table 3 Definition of adverse events
A fatal outcome
Definition of serious adverse reaction Any thrombotic event e.g. stroke, TIA
Major Bleeding- Defined as clinically overt bleeding that is associated with:
• A fall in haemoglobin of 2 g/dl or more, or
• A transfusion of 2 or more units of packed red blood cells or whole blood, or
• A critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular
with compartment syndrome, retroperitoneal, or
• A fatal outcome
Definition of a non serious adverse reaction Defined as overt bleeding not meeting the criteria for major bleeding but associated with
medical intervention, unscheduled contact (visit or telephone call) with a clinician,
(temporary) cessation of warfarin treatment, or associated with discomfort for the subject
such as pain or impairment of activities of daily life.
Examples of non-major clinically relevant bleeding are:
• Epistaxis if it lasts for more than 5 minutes, if it is repetitive (i.e., 2 or more episodes of
true bleeding, i.e., not spots on a handkerchief, within 24 hours), or leads to an intervention
(packing, electrocautery, etc.) and no admission to hospital.
• Gingival bleeding if it occurs spontaneously (i.e., unrelated to tooth brushing or eating),
or if it lasts for more than 5 minutes
• Haematuria if it is macroscopic, and either spontaneous or lasts for more than 24 hours
after instrumentation (e.g., catheter placement or surgery) of the urogenital tract
• Macroscopic gastrointestinal haemorrhage: at least 1 episode of melena or hematemesis,
if clinically apparent
• Rectal blood loss, if more than a few spots
• Haemoptysis, if more than a few speckles in the sputum, or
• Intramuscular hematoma
• Subcutaneous hematoma if the size is larger than 25 cm2 or larger than 100 cm2 if provoked
Definition of serious adverse event A serious adverse event is defined as an untoward medical occurrence in a participant of a
study that does not necessarily have a causal relationship with the treatment that results in:
• Death,
• Is life threatening
• Requires hospitalisation or prolongation of existing hospitalisation
• Results in persistent or significant disability or incapacity
• Consists of a congenital abnormality or birth defect
Other known rare adverse reaction listed in the SmPC are:
Skin reactions: Purpura and ecchymosis
Pruritic lesions
Skin necrosis
Alopecia
Diarrhoea
An unexplained fall in haematocrit
Jaundice and hepatic dysfunction
Fever, nausea, vomiting and pancreatitis
Hypersensitivity reactions are extremely rare and if any of these reactions occur they will
be reported and it will be recommended to the clinician responsible for the participants
warfarin management that warfarin is replaced by an alternative anticoagulant drug
A thrombotic event can also be defined as a serious adverse event related to warfarin.
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Discussion
This study will primarily investigate the role of extending
treatment with oral anticoagulation for those patients
with raised D-dimer levels prior to discontinuing treat-
ment and will study the impact of this management on
both recurrence of thrombosis and development of post-
thrombotic syndrome, both extremely costly outcomes
for the NHS. This strategy would allow those people who
require extended anticoagulation treatment to receive it
whilst ensuring that those who only require short term
treatment are not exposed to unnecessary and potentially
dangerous treatment.
Identifying the potential for utilisation of D-dimer
POC testing will make feasible the identification of
those high risk patients within a primary care setting
negating the necessity for costly and inconvenient refer-
ral elsewhere. Thus people with a first unprovoked
proximal DVT or PE could be managed differently to
current management with the potential for significant
improvements in health outcomes and patient well
being.
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